{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:33:43Z","timestamp":1791250423695,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007678","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000}}],"reference-count":116,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007678.pub2","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T22:01:30Z","timestamp":1326924090000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults"],"prefix":"10.1002","volume":"2012","author":[{"given":"Markus","family":"Schaaf","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"10.1002\/14651858.CD007678.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/11.suppl_1.S91","article-title":"The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)","volume":"11 Suppl 1","author":"Schouten","year":"2000","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1002\/14651858.CD007678.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"Journal of Clinical Oncology : The American Society of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007678.pub2-BIB0003|cit3","first-page":"143","article-title":"European cup: a randomised trial comparing the efficacy of chemotherapy versus purged or unpurged autologous bone marrow transplantation (ABMT) in patients with relapsed follicular non-hodgkin's lymphoma (NHL)","volume":"17","author":"Stade","year":"1994","journal-title":"Onkologie"},{"issue":"21","key":"10.1002\/14651858.CD007678.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007678.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0006|cit6","unstructured":"Sebban C A randomized trial in follicular lymphoma comparing a standard chemotherapy regimen with 4 courses of CHOP followed by autologous stem cell transplant with TBI: the GELF94 trial from GELA European Hematology Association Website http:\/\/www.ehaweb.org. 2003"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0007|cit7","first-page":"104a","article-title":"Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: a result of the randomized GELF94 trial (G.E.L.A. Study Group)","volume":"102.11 Pt 1","author":"Sebban","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007678.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD007678.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007678.pub2-BIB0010|cit10","first-page":"7","article-title":"Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate [abstract]","volume":"31","author":"Ladetto","year":"2003","journal-title":"Bone Marrow Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2404346","article-title":"Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial","volume":"20","author":"Ladetto","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD007678.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Lenz G Dreyling M Schiegnitz E Haferlach T Hasford J Unterhalt M Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group Journal of Clinical Oncology 2004 4926 33","DOI":"10.1200\/JCO.2004.06.016"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdl348","article-title":"Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas-results of a randomized comparison by the German Low-Grade Lymphoma Study Group","volume":"18","author":"Nickenig","year":"2007","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007678.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","article-title":"Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0016|cit16","first-page":"109","article-title":"High dose therapy with autologous purged stem cell transplantation and doxorubicin based immunochemotherapy in patients with advanced follicular lymphoma: A GOELAMS study [Abstract]","volume":"16 Suppl 5","author":"Deconinck","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0017|cit17","first-page":"246a","article-title":"Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: final results of the randomized GOELAMS 064 trial","volume":"102.11 Pt 1","author":"Deconinck","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007678.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"1-2","key":"10.1002\/14651858.CD007678.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000089460","article-title":"Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report","volume":"115","author":"Baldissera","year":"2006","journal-title":"Acta Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007678.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/bbmt.2001.v7.pm11400952","article-title":"High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience","volume":"7","author":"Cao","year":"2001","journal-title":"Biology of Blood & Marrow Transplantation"},{"issue":"11 Pt 2","key":"10.1002\/14651858.CD007678.pub2-BIB0023|cit23","first-page":"268b","article-title":"Prospective randomized study comparing the third generation VACOP-B regimens versus 6 week VACOP-B Plus high-dose sequential followed by autologous bone marrow transplantation in unselected high-risk IPI non Hodgkin's lymphoma. A GEMOH report","volume":"102","author":"Souza","year":"2003","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007678.pub2-BIB0024|cit24","first-page":"349","article-title":"Prospective randomised study comparing 12-week VACOP-B regimen versus 6-week VACOP-B plus high-dose sequential followed by autologous bone marrow transplantation in high-risk IPI aggressive non-Hodgkin lymphoma: a Brazilian GEMOH report [abstract]","volume":"33","author":"Souza","year":"2004","journal-title":"Bone Marrow Transplantation"},{"issue":"18","key":"10.1002\/14651858.CD007678.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.[see comment]","volume":"336","author":"Gianni","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0026|cit26","unstructured":"Guglielmi C Chauvin F Hagenbeek A Somers R Van der LJ Coiffier B The PARMA International randomized prospective study in relapsed non-Hodgkin's lymphoma: second interim analysis of 172 patients and update (as of 20\/11\/92: 200 patients) [abstract] 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 1993"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0027|cit27","first-page":"142","article-title":"The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients)","volume":"7 Suppl 2","author":"Hagenbeek","year":"1991","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0028|cit28","unstructured":"Haioun C Lepage E Gisselbrecht C Coiffier B Bosly A Tilly H Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy in first complete remission aggressive non-Hodgkin's lymphoma (NHL): a study on 469 patients (LNH87 protocol) [abstract] 5th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 1993"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.1994.12.12.2543","article-title":"Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.[see comment]","volume":"12","author":"Haioun","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007678.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007678.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3816\/CLM.2000.n.018","article-title":"CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma","volume":"1","author":"Intragumtornchai","year":"2000","journal-title":"Clinical Lymphoma"},{"issue":"7","key":"10.1002\/14651858.CD007678.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428190500525656","article-title":"Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma","volume":"47","author":"Intragumtornchai","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"22","key":"10.1002\/14651858.CD007678.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \"aggressive\" lymphoma.[see comment]","volume":"20","author":"Kaiser","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.[see comment]","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Leppa S Linna M Nyman H Taimela E Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL) Blood 2006","DOI":"10.1182\/blood.V108.11.3337.3337"},{"issue":"1-2","key":"10.1002\/14651858.CD007678.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0041-1345(00)02769-X","article-title":"Induction of anti-tumor activity following autologous stem cell transplantation: immunotherapeutic implications","volume":"33","author":"Marin","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD007678.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","article-title":"High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study","volume":"14","author":"Martelli","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007678.pub2-BIB0038|cit38","first-page":"78","article-title":"Early autologous stem cell transplantation as first-line therapy in poor prognosis non Hodgkin's lymphoma (NHL): An Italian randomized trial","volume":"10","author":"Martelli","year":"1999","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007678.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0040|cit40","first-page":"2355","article-title":"Peripheral blood stem cell mobilization following salvage chemotherapy (IAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma","volume":"27","author":"Martinez","year":"1995","journal-title":"Transplantation Proceedings"},{"issue":"15","key":"10.1002\/14651858.CD007678.pub2-BIB0041|cit41","first-page":"991","article-title":"Autologous bone marrow transplantation in relapsed non-Hodgkin's lymphoma.[comment]","volume":"334","author":"McBride","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007678.pub2-BIB0042|cit42","first-page":"353, 2002","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"178","author":"Metzner","year":"2002","journal-title":"Strahlentherapie und Onkologie"},{"issue":"2","key":"10.1002\/14651858.CD007678.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/CLM.2005.n.038","article-title":"Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials","volume":"6","author":"Moser","year":"2005","journal-title":"Clinical Lymphoma & Myeloma"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0044|cit44","first-page":"3687","article-title":"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)","volume":"95","author":"Mounier","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdi399","article-title":"Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG","volume":"16","author":"Olivieri","year":"2005","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007678.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.1996.14.2.586","article-title":"Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma","volume":"14","author":"Pettengell","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/2.suppl_1.57","article-title":"PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)","volume":"2 Suppl 1","author":"Philip","year":"1991","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD007678.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.[see comment]","volume":"333","author":"Philip","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0049|cit49","first-page":"390","article-title":"Autologous bone marrow transplantation (ABMT) vs conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma (NHL): final analysis of the Parma randomized study (216 patients) [abstract]","volume":"14","author":"Philip","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0050|cit50","unstructured":"Proctor SJ Phase III Randomized Study of High-Dose Chemotherapy and Radiotherapy Plus Autologous Bone Marrow Transplantation in Patients With Aggressive Non-Hodgkin's Lymphoma National Institutes of Health, ClinicalTrials Gov [http:\/\/www.clinicaltrials.gov] 2003"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD007678.pub2-BIB0051|cit51","first-page":"161a","article-title":"Randomized double blinded trial of rh-GM-CSF in patients with B-cell non-Hodgkin's lymphoma (B-NHL) undergoing high dose chemoradiotherapy and monoclonal antibody purged autologous bone marrow transplantation (ABMT)","volume":"76","author":"Rabinowe","year":"1990","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0052|cit52","first-page":"147","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma","volume":"2 Suppl 2","author":"Rohatiner","year":"1991","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007678.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/annonc\/5.suppl_2.S143","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma","volume":"5 Suppl 2","author":"Rohatiner","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0055|cit55","first-page":"181","article-title":"Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)","volume":"2 Suppl 2","author":"Santini","year":"1991","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0056|cit56","first-page":"S154","article-title":"VACOP-B vs VACOP-B + autologous BM transplantation (ABMT) for aggressive non-Hodgkin's lymphoma. A study of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG) [abstract]","volume":"19 Suppl","author":"Santini","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1002\/14651858.CD007678.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0058|cit58","first-page":"S65","article-title":"High dose chemotherapy followed by autologous stem cell-transplantation in B-high-grade non-hodgkin's lymphoma patients with unfavourable risk factors; a pilot study","volume":"77 Suppl 2","author":"Sonnen","year":"1998","journal-title":"Annals of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD007678.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the european group for blood and marrow transplantation and the united kingdom lymphoma group","volume":"19","author":"Sweetenham","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0060|cit60","first-page":"249","article-title":"The role of high-dose therapy followed by autologous purged stem cell transplantation in previously untreated patients with advanced follicular lymphoma","volume":"4","author":"Winter","year":"2005","journal-title":"Current Hematology Reports"},{"issue":"7","key":"10.1002\/14651858.CD007678.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD007678.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bmt.1705178","article-title":"Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma","volume":"36","author":"Andreadis","year":"2005","journal-title":"Bone Marrow Transplantation"},{"issue":"9383","key":"10.1002\/14651858.CD007678.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007678.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1:CD004629","key":"10.1002\/14651858.CD007678.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004629","article-title":"Interferon-alpha for maintenance of follicular lymphoma","author":"Baldo","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2-3","key":"10.1002\/14651858.CD007678.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02841860151116286","article-title":"A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma","volume":"40","author":"Brandt","year":"2001","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Brown JR Freedman AS ASCT in follicular lymphoma Nature reviews. Clinical Oncology 2009 380 2","DOI":"10.1038\/nrclinonc.2009.87"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/01.moh.0000166499.72138.57","article-title":"Transplantation strategies for patients with follicular lymphoma","volume":"12","author":"Buske","year":"2005","journal-title":"Current Opinion Hematology"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00108-007-1804-2","article-title":"Therapy of follicular lymphoma","volume":"48","author":"Buske","year":"2007","journal-title":"Internist (Berl)"},{"issue":"7","key":"10.1002\/14651858.CD007678.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.10403","article-title":"Changing incidence of non-Hodgkin lymphomas in the United States","volume":"94","author":"Clarke","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0073|cit73","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Deeks","year":"2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10428190701742472","article-title":"Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features","volume":"49","author":"Diaz-Alderete","year":"2008","journal-title":"Leukemia & Lymphoma"},{"issue":"7109","key":"10.1002\/14651858.CD007678.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"38","key":"10.1002\/14651858.CD007678.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin's lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD007678.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2009-0045","article-title":"Role of hematopoietic stem cell transplant in the management of follicular lymphoma","volume":"14","author":"Foster","year":"2009","journal-title":"The Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0080|cit80","first-page":"CD004024","article-title":"High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults","volume":"4","author":"Greb","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"15","key":"10.1002\/14651858.CD007678.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1023\/A:1008375931236","article-title":"The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997","volume":"10","author":"Harris","year":"1999","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD007678.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"x155","DOI":"10.1093\/annonc\/mdl253","article-title":"Current treatment strategies in follicular lymphomas","volume":"17 Suppl 10","author":"Hiddemann","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0086|cit86","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0087|cit87","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0088|cit88","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"23","key":"10.1002\/14651858.CD007678.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/11.suppl_1.S23","article-title":"Follicular lymphoma: have we made any progress?","volume":"11 Suppl 1","author":"Horning","year":"2000","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0091|cit91","first-page":"10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"12","key":"10.1002\/14651858.CD007678.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V80.4.879.879","article-title":"Bcl-2 initiates a new category of oncogenes: regulators of cell death","volume":"80","author":"Korsmeyer","year":"1992","journal-title":"Blood"},{"issue":"7568","key":"10.1002\/14651858.CD007678.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0095|cit95","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Lefebvre","year":"2011"},{"issue":"9","key":"10.1002\/14651858.CD007678.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Lenz G Dreyling M Schiegnitz E Haferlach T Hasford J Unterhalt M Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group Journal of Clinical Oncology 2004 4926 33","DOI":"10.1200\/JCO.2004.06.016"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"9193","key":"10.1002\/14651858.CD007678.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD007678.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Annals of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.01.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review","volume":"16","author":"Oliansky","year":"2010","journal-title":"Biology of blood and marrow transplantation : American Society for Blood and Marrow Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD007678.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007678.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0959-8049(02)00087-4","article-title":"Current treatment of follicular non-Hodgkin's lymphoma","volume":"38","author":"Reiser","year":"2002","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0106|cit106","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.22649","article-title":"Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients","volume":"109","author":"Sacchi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0109|cit109","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","volume":"CD003805","author":"Schulz","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD007678.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0111|cit111","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated March 2011)","author":"Sterne","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD007678.pub2-BIB0112|cit112","first-page":"673","article-title":"Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation","volume":"39","author":"Symmans","year":"1995","journal-title":"Acta Cytologica"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"10","key":"10.1002\/14651858.CD007678.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Oers","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007678.pub2-BIB0115|cit115","first-page":"Art. No.: CD006","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","volume":"Issue 2","author":"Vidal","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007678.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-006-0060-2","article-title":"Investigational strategies in autologous stem cell transplantation for follicular lymphoma","volume":"8","author":"Weigert","year":"2006","journal-title":"Current Oncology Reports"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007678.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T20:17:40Z","timestamp":1731010660000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007678.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007678.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}